The answer so far
Early studies of thymosin alpha-1 for chronic hepatitis B produced different results. One trial found a difference in blood markers against an untreated group; a later, blinded trial did not confirm a statistically significant difference against placebo. Neither result establishes that the peptide cures hepatitis B or replaces current antiviral care.12
On this page
What was the question?
Hepatitis B is an infection caused by a virus that can persist and damage the liver. Thymosin alpha-1 is a peptide studied for its effects on immune responses; researchers investigated whether it could change markers of the virus in people with chronic infection. A changed marker is useful information, but it is not the same question as whether a person has been cured or will avoid liver disease. For the peptide and its different names, see the thymosin alpha-1 profile.31
- 1998: untreated control98 participants; the groups differed in treatment and no placebo was given.
- 1999: blinded placebo97 participants; 7 of 49 versus 2 of 48 met the study’s sustained marker definition.
- Blood markersThe studies measured viral markers; a marker response is not automatically a cure.
- Care todayNeither trial directly compared the peptide with current antiviral options.
What did the 1998 study compare?
The 1998 Taiwan study randomly assigned 98 people with chronic hepatitis B to two thymosin alpha-1 treatment durations or a group followed without specific treatment. At 18 months, 40.6% and 26.5% in the two treatment groups had cleared both HBV DNA and hepatitis B e antigen (HBeAg), compared with 9.4% in the untreated group. The first comparison met the study’s statistical threshold; the second did not. The untreated group did not receive a placebo, so participants and clinicians could know whether treatment was given. These are results for that trial and outcome, not a prediction for an individual.1
What did the later placebo-controlled study find?
In a 1999 multicentre trial, 97 participants with chronic hepatitis B and detectable HBV DNA and HBeAg were assigned thymosin alpha-1 or placebo. Participants and investigators were blinded to the assignment. The trial’s defined sustained marker response during the 12-month study occurred in 7 of 49 people receiving thymosin alpha-1 (14%) and 2 of 48 receiving placebo (4%). The difference was not statistically significant; the authors said it did not confirm the earlier findings. A lack of statistical significance does not prove the treatments are identical, but the trial does not establish the proposed benefit.2
What do those marker names mean?
HBV DNA is genetic material from the virus measured in blood; HBeAg is a viral protein associated with infection. Tests can help clinicians understand a person’s infection, but results need interpretation together with other blood tests and clinical history. In the 1998 trial none of the responders lost hepatitis B surface antigen, another viral marker called HBsAg. The study’s “complete virological response” was its own definition, not proof that every trace of virus disappeared or that a person was cured.123
Why do the two results not settle the question?
They used different controls, populations, definitions and assessment times, and each enrolled fewer than 100 people. The 1998 study used an untreated comparison; the 1999 study used a blinded placebo. Those differences help explain why the results need careful interpretation, although they do not identify the reason the findings differed. Neither trial directly compared thymosin alpha-1 with today’s standard antiviral options, and neither establishes outcomes for all people with hepatitis B. A different question was tested in intensive care: see the sepsis trial.123
What does this mean for care today?
The World Health Organization describes monitoring and antiviral treatment options for people with chronic hepatitis B, with decisions depending on clinical circumstances. Vaccination prevents hepatitis B infection; it does not treat an existing infection. A clinician can explain test results and available care in the relevant country. Do not stop prescribed treatment or replace it with a peptide based on an old study. The immune-support guide explains why immune activity and a health outcome are not interchangeable.34
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- Thymosin alpha-1 in chronic hepatitis B: randomised controlled trialHepatology / PubMed · Randomised trial, 1998
- Thymosin alpha-1 for chronic hepatitis B: placebo-controlled trialJournal of Viral Hepatitis / PubMed · Randomised double-blind trial, 1999
- Guidelines for chronic hepatitis B infectionWorld Health Organization · International clinical guideline, 2024
- Hepatitis BWorld Health Organization · Public-health fact sheet